Format

Send to

Choose Destination
World J Surg. 2019 Aug;43(8):1981-1988. doi: 10.1007/s00268-019-05020-z.

Cardiovascular and Cerebrovascular Events After Parathyroidectomy in Patients on Renal Replacement Therapy.

Author information

1
Clinical Sciences, Lund University, Alwallhuset, Barngatan 2A, 221 85, Lund, Sweden. kerstin.ivarsson@med.lu.se.
2
Department of Nephrology, Skane University Hospital Lund, Lund, Sweden.
3
Department of Urology, Skane University Hospital Malmö, Malmö, Sweden.
4
Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden.
5
National Registry Centre, Skane University Hospital Lund, Lund, Sweden.
6
Department of Internal Medicine, Helsingborg Hospital, Helsingborg, Sweden.
7
Department of Surgery, Skane University Hospital Lund, Lund, Sweden.

Abstract

BACKGROUND:

A majority of patients with end-stage renal disease suffer from secondary hyperparathyroidism, which is associated with osteoporosis and cardiovascular disease. Parathyroidectomy (PTX) is often necessary despite medical treatment. However, the effect of PTX on cardio- and cerebrovascular events (CVE) remains unclear. Data on the effect of PTX from population-based studies are scarce. Some studies have shown decreased incidence of CVE after PTX. The aim of this study was to evaluate the effect of PTX on risk of CVE in patients on renal replacement therapy.

METHODS:

We performed a nested case-control study within the Swedish Renal Registry (SRR) by matching PTX patients on dialysis or with functioning renal allograft with up to five non-PTX controls for age, sex and underlying renal disease. To calculate time to CVE, i.e., myocardial infarct, stroke and transient ischemic attack, control patients were assigned the calendar date (d) of the PTX of the case patient. Crude and adjusted proportional hazards regressions with random effect (frailty) were used to calculate hazard ratios for CVE.

RESULTS:

The study cohort included 20,056 patients in the SRR between 1991 and 2009. Among these, 579 patients had undergone PTX, 423 during dialysis and 156 during time with functioning renal allograft. These patients were matched with 1234 dialysis and 736 transplanted non-PTX patients. The adjusted hazard ratio (HR) with 95% confidence interval (CI) of CVE after PTX was 1.24 (1.03-1.49) for dialysis patients compared with non-PTX patients. Corresponding results for patients with renal allograft at d were HR (95% CI) 0.53 (0.34-0.84).

CONCLUSIONS:

PTX patients on dialysis at d had a higher risk of CVE than patients without PTX. Patients with renal allograft at d on the other had a lower risk after PTX than patients without PTX.

PMID:
31087130
DOI:
10.1007/s00268-019-05020-z

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center